BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 9108408)

  • 1. A synthetic CD4-CDR3 peptide analog enhances bone marrow engraftment across major histocompatibility barriers.
    Koch U; Korngold R
    Blood; 1997 Apr; 89(8):2880-90. PubMed ID: 9108408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloresistance to K locus class I-mismatched bone marrow engraftment is mediated entirely by CD4+ and CD8+ T cells.
    Hayashi H; LeGuern C; Sachs DH; Sykes M
    Bone Marrow Transplant; 1996 Aug; 18(2):285-92. PubMed ID: 8864436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers.
    Colson YL; Wren SM; Schuchert MJ; Patrene KD; Johnson PC; Boggs SS; Ildstad ST
    J Immunol; 1995 Nov; 155(9):4179-88. PubMed ID: 7594573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A synthetic CD4-CDR3 peptide analog enhances skin allograft survival across a MHC class II barrier.
    Koch U; Choksi S; Marcucci L; Korngold R
    J Immunol; 1998 Jul; 161(1):421-9. PubMed ID: 9647252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
    Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts.
    Drobyski WR; Majewski D
    Blood; 1996 Jun; 87(12):5355-69. PubMed ID: 8652851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The contribution of cytotoxic and noncytotoxic function by donor T-cells that support engraftment after allogeneic bone marrow transplantation.
    Jiang Z; Adams GB; Hanash AM; Scadden DT; Levy RB
    Biol Blood Marrow Transplant; 2002; 8(11):588-96. PubMed ID: 12463477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixed allogeneic reconstitution (A+B----A) to induce donor-specific transplantation tolerance. Permanent acceptance of a simultaneous donor skin graft.
    Ildstad ST; Wren SM; Oh E; Hronakes ML
    Transplantation; 1991 Jun; 51(6):1262-7. PubMed ID: 1828637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effect of a CD4-CDR3 peptide analog on graft-versus-host disease across a major histocompatibility complex-haploidentical barrier.
    Townsend RM; Briggs C; Marini JC; Murphy GF; Korngold R
    Blood; 1996 Oct; 88(8):3038-47. PubMed ID: 8874202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4 T cell-mediated alloresistance to fully MHC-mismatched allogeneic bone marrow engraftment is dependent on CD40-CD40 ligand interactions, and lasting T cell tolerance is induced by bone marrow transplantation with initial blockade of this pathway.
    Ito H; Kurtz J; Shaffer J; Sykes M
    J Immunol; 2001 Mar; 166(5):2970-81. PubMed ID: 11207246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans.
    Martin PJ
    J Exp Med; 1993 Aug; 178(2):703-12. PubMed ID: 8101864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric donor cells play an active role in both induction and maintenance phases of transplantation tolerance induced by mixed chimerism.
    Kanamoto A; Maki T
    J Immunol; 2004 Feb; 172(3):1444-8. PubMed ID: 14734720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic versus semiallogeneic F1 bone marrow transplantation into sublethally irradiated MHC-disparate hosts. Effects on mixed lymphoid chimerism, skin graft tolerance, host survival, and alloreactivity.
    Pierce GE
    Transplantation; 1990 Jan; 49(1):138-44. PubMed ID: 2137269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of allogeneic marrow graft rejection by donor T cells that do not recognize recipient alloantigens: potential role of a veto mechanism.
    Martin PJ
    Blood; 1996 Aug; 88(3):962-9. PubMed ID: 8704255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A CD4 domain 1 CC' loop peptide analogue enhances engraftment in a murine model of bone marrow transplantation with sublethal conditioning.
    Varadi G; Friedman TM; Korngold R
    Biol Blood Marrow Transplant; 2005 Dec; 11(12):979-87. PubMed ID: 16338620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10).
    Ildstad ST; Wren SM; Bluestone JA; Barbieri SA; Stephany D; Sachs DH
    J Immunol; 1986 Jan; 136(1):28-33. PubMed ID: 2933464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigen-primed CD8+ T cells can mediate resistance, preventing allogeneic marrow engraftment in the simultaneous absence of perforin-, CD95L-, TNFR1-, and TRAIL-dependent killing.
    Komatsu M; Mammolenti M; Jones M; Jurecic R; Sayers TJ; Levy RB
    Blood; 2003 May; 101(10):3991-9. PubMed ID: 12521999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor CD4+CD25+ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation.
    Hanash AM; Levy RB
    Blood; 2005 Feb; 105(4):1828-36. PubMed ID: 15494429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of host T cell subsets in bone marrow rejection directed to isolated major histocompatibility complex class I versus class II differences of bm1 and bm12 mutant mice.
    Vallera DA; Taylor PA; Sprent J; Blazar BR
    Transplantation; 1994 Jan; 57(2):249-56. PubMed ID: 7906058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
    Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
    Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.